Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties

Dipeptidyl peptidase 9 (DPP9) is a key regulator of pyroptosis in leukocytes. DPP9-targeting inhibitors have been reported to selectively induce pyroptosis in human acute myeloid leukemia (AML) cells and work synergistically with non-nucleoside reverse transcriptase inhibitors (NNRTIs) to kill HIV-1-infected lymphocytes. Here, we report structure-activity relationship data for a novel series of low nanomolar DPP9 inhibitors with unprecedented pyroptosis-inducing potency and kinetics. They have substantial DPP9-to-DPP8 selectivity and full selectivity over other related peptidases, including DPP4. The selected compound <b>6e</b> was administered to healthy rats and demonstrated high oral bioavailability, along with a long <i>in vivo</i> and microsomal half-life. Finally, we also investigated the pyroptosis induction potential in HIV-1-infected T-lymphocytes. These new compounds have the potential to become important research tools and support further progress in DPP9's therapeutic potential.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-10-29
DOI
https://doi.org/10.1021/acs.jmedchem.5c02049
Primary Topic
Peptidase Inhibition and Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties

Nicolò Filippi, Ingrid De Meester, Koen Augustyns, Emile Verhulst et al.
Journal of Medicinal Chemistry
Peptidase Inhibition and Analysis
article

Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties

Nicolò Filippi, Ingrid De Meester, Koen Augustyns, Emile Verhulst, Dominique Schols, Pim‐Bart Feijens, Vanesa Nozal, R. Hermans, Margarida Espadinha, Pieter Van der Veken, Guy Caljon, Sarah G.J.A. Peeters, Tiphanie Gomard, Laura Dirkx, Siham Benramdane, Joni De Loose, Sam Corthaut, K. Mertens
article en

Abstract

Dipeptidyl peptidase 9 (DPP9) is a key regulator of pyroptosis in leukocytes. DPP9-targeting inhibitors have been reported to selectively induce pyroptosis in human acute myeloid leukemia (AML) cells and work synergistically with non-nucleoside reverse transcriptase inhibitors (NNRTIs) to kill HIV-1-infected lymphocytes. Here, we report structure-activity relationship data for a novel series of low nanomolar DPP9 inhibitors with unprecedented pyroptosis-inducing potency and kinetics. They have substantial DPP9-to-DPP8 selectivity and full selectivity over other related peptidases, including DPP4. The selected compound <b>6e</b> was administered to healthy rats and demonstrated high oral bioavailability, along with a long <i>in vivo</i> and microsomal half-life. Finally, we also investigated the pyroptosis induction potential in HIV-1-infected T-lymphocytes. These new compounds have the potential to become important research tools and support further progress in DPP9's therapeutic potential.

Journal of Medicinal ChemistryVol. 68(21)
University of Antwerp (BE), Rega Institute for Medical Research (BE), de Duve Institute (BE), UCLouvain (BE)
Openalex Percentile: Top 58%
Peptidase Inhibition and Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.